Pantherna Therapeutics GmbH
Innovation & Business Idea
Pantherna Therapeutics is a biopharmaceutical company developing first-in-class therapeutics for vascular diseases by restoring endothelial cell function.
Customers / Target Market
Biotech & Big Pharma
Biotech & Big Pharma (Nucleic acid based Therapeutics)
Intellectual Property Status
Patent applications in preparation
Development Status & Future Steps
Research & Preclinical
Trade sale & IPO
Dr. Klaus Giese, CEO. Former CEO/CSO, Erdmann Technologies, Berlin; CSO, Silence Therapeutics, London/Berlin; Senior Scientist, Chiron Corporation, Emeryville; Scientist, HHMI, Univ. of California, San Francisco (UCSF); PhD Biochemistry, Berlin. Dr. Jörg Kaufmann, CSO. Former CSO, Silence Therapeutics, London/Berlin; Senior Scientist, Chiron Corporation, Emeryville; Group Leader Institute of Tumor Biology (IMT), Marburg; Postdoctoral Fellow, HHMI, Univ. of California, Los Angeles (UCLA), PhD Molecular Genetics, Marburg. Dr. Oliver Keil, COO. Former Head of CMC, Silence Therapeutics, London/Berlin; Head of Chemistry & Formulation, G.O.T. Therapeutics, Berlin; Postdoctoral Fellow/ Group leader Non-viral Gene Transfer, University of Düsseldorf, PhD Chemistry, Wuppertal. Dr. Gerrit Maass, CFO. Former CEO/CFO Erdmann Technologies, Berlin; General Counsel at MetrioPharm GmbH, Berlin; Accredited and fully qualified lawyer; PhD in Political Sciences, TU Braunschweig; BSc in plant biotechnology, Hannover.
Searching forCommercial Partner, Funding, Collaboration